Expanded Access Policy

We are a clinical stage biopharmaceutical company engaged in the development of small-molecule therapeutics targeting age-related degenerative diseases. We currently have several clinical studies planned or underway that are designed to measure safety and efficacy of our experimental medications for patients with Alzheimer’s disease, dry age-related macular degeneration and dementia with Lewy bodies.

At this time, we do not offer expanded access to any of our therapies in development. Rather, before our drug candidates complete their clinical development and are reviewed and approved by regulatory authorities, they can only be accessed through participation in our clinical trials.

We believe the best way for patients to potentially benefit from experimental drug therapies is through participation in clinical studies. You can find additional information about our ongoing clinical trials at www.clinicaltrials.gov. If you have questions about any of the studies you see listed there, please consult with your physician.